Author:
Wiatrowski Kyle,Kim Tae Hee,Przespolewski Amanda
Abstract
Immunotherapy has without question revolutionized the treatment of both hematologic and solid malignancies. Over the last several years novel strategies are being developed to incorporate these groundbreaking therapies into the care of patients with AML. Here we present an overview of the recent developments in immunotherapy for AML with a focus on biomarkers of response. Topics reviewed include antibody drug conjugates, BiTEs, DARTs, checkpoint inhibitors, and cellular therapy as well as the development of biomarkers predictive of response in each class.
Reference64 articles.
1. Cancer Stat Facts: Leukemia — Acute Myeloid Leukemia (AML)2021
2. Frequency of Prolonged Remission Duration After High-Dose Cytarabine Intensification in Acute Myeloid Leukemia Varies by Cytogenetic Subtype;Bloomfield;Cancer Res,1998
3. Treating Acute Myeloid Leukemia in Older Adults;Wang;Hematol Am Soc Hematol Educ Program,2014
4. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia;DiNardo;N Engl J Med,2020
5. 10-Day Decitabine With Venetoclax for Newly Diagnosed Intensive Chemotherapy Ineligible, and Relapsed or Refractory Acute Myeloid Leukaemia: A Single-Centre, Phase 2 Trial;DiNardo;Lancet Haematol,2020
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献